Skip to content

The Effect of L-Carnitin in Treatment of Migraine

Comparison of the Effectiveness of L-Carnitin and Propranolol in Prophylaxis of Headache Attacks in Migrainous Children

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190128042533N1
Enrollment
88
Registered
2019-03-02
Start date
2019-01-22
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine

Interventions

Intervention 1: Intervention group: In this group, patients are treated with 50 mg/kg L-carnitine daily. Intervention 2: Intervention group: In this group, patients are treated with 1 mg/kg Propranolo

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 15 Years

Inclusion criteria

Inclusion criteria: Children with migraine whose disease has recently been diagnosed with the International Headache Society (IHS) criteria. Not currently under any preventive treatment. Have a migraine headache for at least once a week.

Exclusion criteria

Exclusion criteria: Patients who have more than four headache attacks in a month (severe migraines)

Design outcomes

Primary

MeasureTime frame
Headache severity. Timepoint: Two weeks, one month, three months after begining of treatment. Method of measurement: Pediatric Migraine Disability Assessment Scale.;Headache frequency. Timepoint: Two weeks, one month, three months after begining of treatment. Method of measurement: interview.;Headache duration. Timepoint: Two weeks, one month, three months after begining of treatment. Method of measurement: Interview.

Secondary

MeasureTime frame
Medication side effects. Timepoint: Two weeks, one month, three months after begining of treatment. Method of measurement: Physical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLaya Amini

Esfahan University of Medical Sciences

layaamini66@yahoo.com+98 31 3673 6515

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026